Intervention and procedures
fever
BLOOD
During the multiple dose stage, participants received the standard dose of ivermectin 200 μg/kg once daily for one, two, or three days, respectively. In the randomized-controlled trial stage, participants received either ivermectin 300 μg/kg once daily for three days or placebo once daily for three days, based on dosage in a previous trial administering ivermectin to Placebo tablets were Winthrop's At enrolment, participants underwent physical examination with demographic data and medical history recorded. Blood samples were taken for haematology (red blood cell count, haemoglobin, haematocrit, leukocyte count with differential and platelet count), clinical chemistry (AST, ALT, urea, creatinine, CRP, and electrolytes), urinalysis, thick and thin blood smears, and for quantitative polymerase chain reaction (qPCR). Blood pregnancy tests were performed at baseline for female participants. Participants were hospitalized for 72 h. Following discharge from the research centre, participants returned for outpatient visits at days 4, 5, 6, and 7. Participants received rescue medication with artemether-lumefantrine (Novartis Coartem® 80/480) in case of fever (axillary temperature >38.5 °C) in conjunction with any 